Stockscreener 앱 받기
17.89
1.94%
0.34
시간 외 거래:
17.89
전일 마감가:
$17.55
열려 있는:
$17.95
하루 거래량:
714.66K
Relative Volume:
0.88
시가총액:
$1.23B
수익:
$161.10M
순이익/손실:
$-308.60M
주가수익비율:
-3.8308
EPS:
-4.67
순현금흐름:
$-259.90M
1주 성능:
-0.61%
1개월 성능:
-5.84%
6개월 성능:
-33.96%
1년 성능:
-54.67%
1일 변동 폭
$17.65
$18.30
1주일 범위
$17.46
$19.30
52주 변동 폭
$17.08
$53.08
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
ARVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
17.89 | 1.23B | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Citadel Advisors LLC's Strategic Acquisition of Arvinas Inc. Sha - GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
When the Price of (ARVN) Talks, People Listen - Stock Traders Daily
The Escalator: Merck, Novartis, Arvinas and more - MM+M Online
Brokers Set Expectations for Arvinas FY2025 Earnings - MarketBeat
Arvinas terminates lease agreement, frees up future liabilities - Investing.com India
Arvinas terminates lease agreement, frees up future liabilities By Investing.com - Investing.com Australia
Arvinas Holding Company Adjusts Real Estate Strategy - TipRanks
Assenagon Asset Management S.A. Buys 777 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas looks for new chief commercial officer - The Pharma Letter
Arvinas Repeat Insider Selling Not A Positive Indicator - Simply Wall St
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - The Motley Fool
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Average PT from Analysts - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? - MSN
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowShould You Sell? - MarketBeat
Arvinas stock touches 52-week low at $17.35 amid market challenges - Investing.com Australia
Arvinas outlines 2025 clinical trial plans for breast cancer drug By Investing.com - Investing.com Australia
Arvinas Announces Updates on Clinical Trials Progress - TipRanks
Arvinas outlines 2025 clinical trial plans for breast cancer drug - Investing.com India
Arvinas Updates Guidance for First- and Second-Line Phase 3 - GlobeNewswire
Arvinas Plans Two Phase 3 Trials for Breakthrough Breast Cancer Drug, Expands Pipeline for 2025 - StockTitan
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update - Business Upturn
Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation - Barchart
Metastatic Prostate Cancer Market to Expand Significantly - openPR
JPMorgan Chase & Co. Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
JPMorgan Chase & Co. Increases Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas (NASDAQ:ARVN) Trading 9.2% HigherHere's Why - MarketBeat
How To Trade (ARVN) - Stock Traders Daily
March 21st Options Now Available For Arvinas (ARVN) - Nasdaq
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 6.5% - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Increase in Short Interest - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Consensus Target Price from Brokerages - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Arvinas (NASDAQ:ARVN) Shares Down 3.3%Should You Sell? - MarketBeat
Arvinas' Vepdegestrant: Why The Data May Not Hold Up (NASDAQ:ARVN) - Seeking Alpha
Barclays PLC Purchases 80,984 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by State Street Corp - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat
New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal
New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.49%
0.79%
자본화:
|
볼륨(24시간):